Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
Table 1
Patient and disease characteristics within the mITT population.
Characteristic
Fidaxomicin
Vancomycin
Total
Female, number (%)
127 (63.2)
125 (61.0)
252 (62.1)
UBMs per day, mean (SD)
8.1 (4.2)
7.8 (4.5)
8.0 (4.3)
Inpatient, number (%)
107 (53.2)
105 (51.2)
212 (52.2)
CDI antibiotics within previous 24 hours, number (%)
59 (29.4)
63 (30.7)
122 (30.0)
Previous CDI episode, number (%)
39 (19.4)
37 (18.0)
76 (18.7)
Severe CDI, number (%)
83 (41.3)
80 (39.0)
163 (40.1)
Age ≥ 65 years, number (%)
93 (46.3)
92 (44.9)
185 (45.6)
Antibiotic use†, number (%)
43 (21.4)
37 (18.0)
80 (19.7)
Cancer, number (%)
23 (11.4)
31 (15.1)
54 (13.3)
Renal dysfunction‡, number (%)
119 (59.2)
107 (52.2)
226 (55.7)
BI strain§, number (%)
66 (40.0)
67 (37.9)
133 (38.9)
Severe CDI at baseline: ≥10 UBMs per day or white blood cell count > 15,000/mm3. †Other than CDI treatment, during either CDI treatment or follow-up period. ‡Renal impairment at baseline: creatinine clearance < 90 mL/min/1.73 m2. §Percentages are calculated from all patients and not from the 342 patients for whom strain type was available. BI, BI/NAP1/027; CDI, Clostridium difficile infection; mITT, modified intention-to-treat; SD, standard deviation; UBMs, unformed bowel movements.
